Grifols, S.A. (NASDAQ:GRFS – Get Rating) shares reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $7.27 and last traded at $7.41, with a volume of 7468 shares trading hands. The stock had previously closed at $7.74.
Analyst Upgrades and Downgrades
GRFS has been the topic of several research analyst reports. Jefferies Financial Group began coverage on Grifols in a research note on Monday, July 25th. They set a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on Grifols from €17.00 ($17.35) to €16.00 ($16.33) and set a “hold” rating on the stock in a report on Tuesday, August 2nd. JPMorgan Chase & Co. dropped their target price on Grifols from €11.50 ($11.73) to €10.30 ($10.51) in a report on Wednesday, September 14th. Finally, Berenberg Bank boosted their target price on Grifols from €20.15 ($20.56) to €20.30 ($20.71) and gave the stock a “buy” rating in a report on Friday, July 15th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Grifols currently has a consensus rating of “Hold” and an average price target of $15.53.
Grifols Stock Down 7.8 %
The company has a 50 day moving average price of $8.76 and a two-hundred day moving average price of $10.66. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.68 and a quick ratio of 0.91. The stock has a market cap of $4.91 billion, a PE ratio of 6.70 and a beta of 0.31.
Institutional Trading of Grifols
Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.
- Get a free copy of the StockNews.com research report on Grifols (GRFS)
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.